Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ibrutinib dose-finding, pharmacokinetics, safety, and efficacy study in chronic graft-versus-host disease
NL-OMON59716Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibrutinib in chronic graft-versus-host disease (cGVHD) (3 cohorts), sponsored by AbbVie Inc. Primary endpoints: Pharmacokinetics to determine recommended pediatric equivalent dose and Pharmacokinetics and safety. Started Nov 2019; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NL-OMON59716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59716.